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E-mail: jerrychan@nus.edu.sgThe safe correction of an inherited bleeding disorder in utero
prior to the onset of organ damage is highly desirable. Here,
we report long-term transgene expression over more than
6 years without toxicity following a single intrauterine gene
transfer (IUGT) at 0.9G using recombinant adeno-associated
vector (AAV)-human factor IX (hFIX) in the non-human
primatemodel we have previously described. Four of six treated
animals monitored for around 74 months expressed hFIX at
therapeutic levels (3.9%–120.0%). Long-term expression was
6-fold higher in males and with AAV8 compared to AAV5,
mediated almost completely at this stage by random genome-
wide hepatic proviral integrations, with no evidence of hot-
spots. Post-natal AAV challenge without immunosuppression
was evaluated in two animals exhibiting chronic low transgene
expression. The brief neutralizing immune reaction elicited
had no adverse effect and, although expression was not
improved at the dose administered, no clinical toxicity was
observed. This long-term surveillance thus conﬁrms the safety
of late-gestation AAV-hFIX transfer and demonstrates that
postnatal re-administration can be performed without immu-
nosuppression, although it requires dose optimization for the
desired expression. Nevertheless, eventual vector genotoxicity
and the possibility of germline transmission will require life-
long monitoring and further evaluation of the reproductive
function of treated animals.
INTRODUCTION
In-utero molecular correction of a genetic disease offers an oppor-
tunity to completely avoid end-organ damage in conditions that
manifest early in life. We have demonstrated that supra-physiolog-
ical human factor IX (hFIX) expression during the perinatal period
is achievable with adeno-associated vector (AAV)-mediated intra-
uterine gene transfer (IUGT) in late gestation, an approach which
may arbitrate the risk of perinatally lethal events like intracranial
hemorrhage from similar clotting factor deﬁciencies.1–4 This strat-Mole
This is an open access article under thegy leverages on fetal cells being the better recipients for therapeutic
vehicles, given their superior transduction and differentiation efﬁ-
ciencies, and may be used to treat genetic diseases diagnosed late
in pregnancy in the immunologically mature fetus.1,5–8 The key clin-
ical challenges of AAV-IUGT concern the long-term safety in
the treated fetus, namely (1) oncogenic potential of these clinical
AAV vectors; (2) durability of therapeutic expression; and (3) risk
of germ-line transmission of proviral DNA. The threat of insertional
mutagenesis still presents one of the most daunting obstacles in the
clinical translation of both prenatal and postnatal gene transfer.
Although AAVs remain primarily episomal and are less likely to
induce oncogenesis than oncoretroviruses and lentiviruses,9,10 the
low-frequency integration events found in adult, neonatal, and fetal
animal models1,11,12 raise the possibility of malignant transforma-
tion by disruption of tumor suppressor genes or activation of
proto-oncogenes.13 In fact, AAV-related hepatocellular genotoxicity
reported in rodents11,14,15 and the presence of wild-type AAV2 inte-
gration sites documented in biopsies from patients with hepatocel-
lular carcinoma16 highlight the need for a proper safety assessment.
Moreover, because oncoretroviral-mediated oncogenesis has been
linked to integration at sites of active gene transcription,10 we antic-
ipate that post-treatment oncogenic events are more likely during
fetal life when genes are more actively transcribed than at any other
developmental stage.17cular Therapy Vol. 25 No 8 August 2017 ª 2017 The Authors. 1843
e CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1. Offspring Biodata and Outcomes following IUGT
ID (Sex)
IUGT Dose
(vg/kg)
GA at Birth
(Days)
Birth
Weight (g)
hFIX, Normal Antigen (%) (±
SD) Postnatal Challenge
Longest Follow-up
Period (Months)Peak Steady State Age (Months) Dose (vg)
hFIX at Last
Time Point (%)
8-002 (M) 1.5  1013 143 275 656.5 (33.2) 109.6 (32.7) Not done 100 11
8-006 (M) 1.4  1013 148 290 566.3 (474.0) 35.6 (17.5) Not done 24.8 51
8-007a (F) 1.4  1013 147 280 4.8 (3.0) 0.4 (1.0)
30 AAV8, 3.98E+11
46 AAV5, 4.36E+11 0.0 62
5-002 (M) 1.5  1013 143 260 122.6 (57.9) 16.9 (7.0) Not done 10.9 71
5-006 (F) 1.9  1013 145 205 51.4 (48.9) 3.0 (3.1) 32 AAV5, 4.82E+11 3.7 63
5-007 (F) 1.6  1013 147 255 21.3 (5.8) 5.4 (3.5) Not done 1.6 63
ID, identity number.
aSubject not included in the previous paper.1
Molecular TherapySpeciﬁc concerns arise from the current knowledge of AAV gene
therapy of direct relevance to the clinical application of IUGT. We
previously demonstrated that vector load and transgene expression
diminish as the AAV-IUGT recipient undergoes rapid neonatal
growth, which in the clinical context could lead to sub-therapeutic
expression after the initial peak.1,7 In this event, a postnatal vector
boost would have to be considered if transgene expression is needed
life-long. Sex-speciﬁc differences in the stability of hepatocyte AAV-
transduction and transgene expression have been described in
postnatally treated murine subjects, with males consistently outper-
forming females due to greater endogenous testosterone production
and androgen receptor-binding sites around the transgene pro-
moter.18,19 This pattern was not observed in adult macaques because
equivalent transduction and expression were observed in males and
females with AAV-FVII delivery, leading us to originally conclude
that these observations were murine speciﬁc.20 Additionally, viral
transmigration across the blood-gonadal barrier presents the possibil-
ity of germ-line transmission, of which the resulting reproductive
toxicity, if any, should be deﬁned.21,22 The resolution of these critical
questions is of urgent importance in the clinical translation of this
promising strategy and can only be reliably addressed in a relevant
preclinical non-human primate model.23,24 Using the experimental
paradigm of hemophilia B with its modest therapeutic goal of 1%
hFIX activity, we present the longest follow-up in a macaque model
ever reported and describe the variables that will be impactful in
gene therapy applications.
RESULTS
Demographics
12 fetuses were injected at 0.9G with a single dose of AAV-FIX, and
six infants survived; the causes of premature mortality were previ-
ously described1 (Table 1). These animals received a mean dose of
1.6E+13 vector genomes (vg) (SD ± 0.19), had a mean birth weight
of 260.8 ± 27.6 g and were monitored to an age of 53.5 ± 19.9 months.
AAV8 recipients (n = 3) included two males and one female, and
AAV5 recipients (n = 3) comprised two females and one male. Two
recipients were selected for postnatal vector challenge to dropping1844 Molecular Therapy Vol. 25 No 8 August 2017or persistently low expression with a deliberately low dose of AAV
due to safety concerns with higher doses.25
Transgene Levels, Vector Load, and Expression Efficacy
following IUGT
In our previously reported 22-month follow-up, we observed a stable
hFIX expression peaking 30–60 days after delivery, followed by a
rapid decline to a stable plateau.1 We have longitudinally monitored
six animals; 8007 is reported here for the ﬁrst time (Table 1). Peak
expression was observed to occur within the ﬁrst 60 days of delivery
in most animals and ranged from 656.5 ± 33.2% in 8002 to 4.8 ± 3.0%
in 8007, which occurred sporadically at 5 months in this animal.
Mean steady-state expression from day 60 was 109.6 ± 32.7% in
8002 and 35.6 ± 17.5% in 8006 over 11 and 61 months of observation,
respectively. 8007 had much lower mean hFIX levels of 0.4 ± 1.0%
over 72 months. Peak expression was highest in 5002 at 122.6 ±
57.9% and lowest in 5007 at 21.3 ± 5.8%. Mean steady-state expres-
sion among AAV5 subjects was 16.9 ± 7.0% in 5002, 3.0 ± 3.1% in
5006, and 5.4 ± 3.5% in 5007 over 74–82 months of observation.
This was maintained despite weight gain, which increased by almost
16-fold by 4 years of age (Figures 1A–1F). Overall mean expression
was 3-fold higher among AAV8 infants than AAV5 infants over a
period of 71 months at 31.6 ± 58.8% and 10.8 ± 9.2%, respectively
(p = 0.003). This was signiﬁcant both during the periods of peak
(216.9 ± 138.6% versus 41.8 ± 20.8%, p = 0.04) and steady-state
expression (19.4 ± 2.2% versus 9.0 ± 0.4%, p < 0.0001) in AAV8
and AAV5, respectively. However, 8007 showed hFIX levels just
over detection limits at 0.4 ± 0.9% over 62 months (Figure 1C),
whereas expression in 5006 fell to <1% around 15–20 months (Fig-
ure 1E). Both were eventually challenged postnatally with another
dose of AAV (black arrows); 5006 levels ﬂuctuated randomly, and
expression was 1.3% at the time of the second injection. There
was only mild transient increase in hFIX in 5006 (to 4.8% 2 months
after re-injection) and no discernible improvement in 8007, even with
a second challenge at 46 months using AAV5 to circumvent existing
anti-AAV8 capsid-speciﬁc antibodies. hFIX levels at ﬁnal assessment
are shown in Table 1. Assessment of vector load post-challenge
(legend on next page)
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Figure 2. Efficacy of Transgene Expression
(A) Liver, skin, and peripheral fat showed stable low-level VCN between 6 and 48 postnatal months. VCN at 6 months was higher in muscle and omentum compared with the
liver at 6 months and decreased rapidly thereafter. Vector copies persisted at stable low levels in the liver and other tissues in the presence of continued growth. (B) AAV8
recipients demonstrated more efficient expression (533.9 ± 748.4% hFIX activity per vector copy versus 68.6 ± 138.4% per vector copy with AAV5, ns). Comparison
of individual hepatic VCN shows a 1 to 2 log-fold decrease in 5006 compared to other AAV5 recipients, whereas VCN in 8007 was lower than that in 8006 to the same extent.
(C) Males had a log-fold higher hFIX expression than did females (38.9 ± 59.6% versus 3.6 ± 3.9%, p < 0.0001) throughout the surveillance period, (D) with a non-significant
trend toward higher expression efficacy (210.1 ± 436.9% versus 20.1 ± 32.5% per vector copy in females). Error bars in (A) and (C) indicate SD.
Molecular Therapydemonstrated stable VCN in 5006 (0.3 copies/cell) and a reduction
from 0.04 to 0.001 copies/cell in 8007 post-challenge (Figure 1G). We
did not analyze the functionality of hFIX protein through coagulation
assays.
Hepatic vector copy number (VCN) in all organs had dropped be-
tween one and three log-folds by 18 postnatal months, with no statis-
tical differences between them; mean hepatic VCN was 1.9 ± 2.1
copies/cell and omentum carried the highest load at 5.5 ± 11.0
copies/cell, whereas the vector load ranged from 0.2 to 1.6 copies/
cell in skin, fat, and skeletal muscle (Figure 2A). Hepatic vector
load was one log-fold higher in AAV8 than in AAV5 infants at allFigure 1. Transgene Expression in IUGT Recipients
(A–F) hFIX levels peaked around 30–60 days postnatal and rapidly fell to a steadily ma
during infancy; (A) 8002, (B) 8006, (C) 8007, (D) 5002, (E) 5006, (F) 5007. Expression wa
observation, and was higher with AAV8 during both peak and steady-state periods. 500
with another dose of AAV (arrows). (G) Despite this, there was only mild transient incr
demonstrated stable VCN in 5006 (0.3 copies/cell) and a reduction from 0.04 to 0.00
1846 Molecular Therapy Vol. 25 No 8 August 2017biopsy time points until around 3 years after birth, with 4.8 ± 4.9
copies/cell and 0.6 ± 0.4 copies/cell, respectively (p = 0.03, Figure 2B).
Taking into account all biopsy time points over 48 months and the
disproportionate distribution of males and females between serotype
groups, AAV8 recipients demonstrated more efﬁcient expression of
hFIX (Figure 2B). For each hepatic vector copy, 533.9 ± 748.4%
hFIX activity was achieved compared with 68.6 ± 138.4% activity
per vector copy with AAV5 (not signiﬁcant [ns]). Treated males
had substantially higher hFIX levels regardless of AAV serotype
used (Figure 2C). Overall expression was higher in males than in
females (38.9 ± 59.6% versus 3.6 ± 3.9%, p < 0.0001), a trend seen dur-
ing both peak (243.5 ± 151.7% versus 15.2 ± 7.3%, p = 0.02) andintained plateau level that was observed in most subjects despite the rapid growth
s maintained at 31.6 ± 58.8% (AAV8) and 10.8 ± 9.2% (AAV5) over 11–71 months of
6 and 8007 exhibited suboptimal expression (<1%) and were challenged postnatally
ease in 5006 and no discernible improvement in 8007. Assessment of vector load
1 copies/cell in 8007 about 1 month post-challenge.
Figure 3. Immunogenicity of IUGT
(A) AAV8 recipients maintained low-level anti-AAV8 IgG
after IUGT, which steadily increased following postnatal
vector challenges in 8007 (arrows). Recipients of AAV5
mounted a more robust IgG response sustained for a year
post-IUGT. (B) A single vector challenge to 5006 did
not cause a substantial shift in IgG expression (arrow).
(C) Expression in 8007 remained sub-therapeutic after
both vector challenge (VC) (broken lines) at 30 and
46 months of age, peaking at 1.3% after the second
challenge. Anti-AAV Ab levels remained subclinical.
(D) NAbs were detected briefly by >50% loss of GFP
expression in previously transduced cells in vitro.
(E) Similar observations were made in 5006 in following
VC (broken line) at 32 months; anti-AAV5 Abs remained
stable. Upper dotted line in (C) and (E) indicates positive
threshold for IgG response; lower dotted line indicates
therapeutic minimum of 1% hFIX activity. (F) In 8007, IL-2
and TNF-a was expressed in 2% of CD8 central memory
cells at week 1 and was no longer detectable by week 2
(positive 23.5% IL-2, TNF-a, and INF-g; negative 1%
expression). (G) 5006 showed intermittent increases in
liver-specific ALT following VC (arrowhead), whereas
minimal responses were observed in 8007 (arrows).
Intermittent fluctuations in AST were observed before and
after VC in both animals.
www.moleculartherapy.orgplateau phases (27.4 ± 15.7 versus 2.9 ± 2.0, p < 0.0001). Mean hepatic
VCNwas similar inmales (2.8 ± 3.3 copies/cell) and females (1.2 ± 1.3
copies/cell over 48 months of surveillance, ns). This resulted in a non-
signiﬁcant trend toward a higher hFIX expression per vector copy in
males than females (210.1 ± 436.9% versus 20.1 ± 32.5% per vector
copy, Figure 2D).
Immunotoxicity and Genotoxicity
Next, we investigated the potential of AAV-IUGT to trigger an
immune response. Besides the initial humoral reaction previously
described,1 continued surveillance showed that anti-AAV8-binding
antibodies (Abs), initially peaking in the ﬁrst 3–6 months, subse-
quently settled below the positive threshold for most of the remainingMolecsurveillance period (Figure 3A). Macaque 8007,
exhibiting the lowest transgene expression,
showed the most pronounced humoral
response of AAV8 animals and maintained
levels above the positive threshold for 7 months
before resolution. Macaques 5002, 5006, and
5007 demonstrated a much more robust and
prolonged anti-AAV5 reaction until 15 months,
after which immunoglobulin G (IgG) expres-
sion dropped below the positive threshold for
the remaining surveillance period (Figure 3B).
Re-injected animals were checked for anti-
AAV antibodies prior to postnatal treatment,
which were found to be below the positive
threshold (Figures 3A and 3B). Anti-AAV8IgG in 8007 did not cross-react to AAV5. Expression in 8007 re-
mained sub-therapeutic after vector challenges at 30 and 46 months
of age, peaking at 1.4% after the second challenge. Prior to the ﬁrst
challenge, mean hFIX was 0.2 ± 0.3%; there was no change in expres-
sion with the ﬁrst challenge of AAV8 (0.1 ± 0.2%) or with the second
challenge of AAV5 (0.4 ± 0.5%, ns, Figure 3C). Anti-AAV-binding
Ab levels remained subclinical, whereas neutralizing antibodies
(NAbs) were detected for 20–30 days after challenges with both
AAV8 and AAV5 by observing a dramatic drop in GFP-transduced
293T cells (to <50% baseline transduction), indicative of a brief
neutralizing effect (Figures 3C and 3D). hFIX in 5006 increased
brieﬂy to 4.8% approximately 3 to 4 months post-challenge with
AAV5, with another peak of 13.0% at 53 months of age, 21 monthsular Therapy Vol. 25 No 8 August 2017 1847
Figure 4. Vector Integration Analyses
(A) Gel electrophoresis of LAM-PCR products retrieved from the different samples and negative controls (untransduced genomic DNA and threewater controls) usingMseI for
restriction digest. Broken lines indicate two separate gels in the same image. Despite the presence of bands in the untransduced DNA control, due to homologies between
the vector and genomic sequences, no amplification was obtained in the sequencing library preparation, indicating that only AAV-derived amplicons were used in later
analyses. Due to AAV concatemers, which are also amplified by LAM-PCR, not all bands correspond to ISs. (B) Relative sequence counts of the ten most prominent ISs
retrieved were calculated in relation to all uniquely mappable IS sequences. The RefSeq identity of the gene located adjacent to or at the IS are listed. (C) Chromosomal
distribution of retrieved ISs was analyzed and compared to a synthetic random dataset of 8,628 ISs to determine eventual integration hotspots. (D) Distribution of the ISs
within gene coding and nearby regions in comparison to a random dataset.
Molecular Therapypost-challenge. Pre-challenge mean hFIX was 2.6 ± 2.4%, whereas
post-challenge hFIX was 2.5 ± 2.6% (ns). Anti-AAV5 antibody levels
remained stable, and NAbs were detected by day 7 and remained
elevated for 35–40 days (Figures 3D and 3E). Anti-hFIX IgG expres-
sion was consistently negative throughout (data not shown). Evidence
of cellular immune response to AAV capsid proteins were found in
the ﬁrst week after the ﬁrst vector challenge in 8007, where central,
but not effector, memory CD8 T cells demonstrated interleukin-2
(IL-2) and tumor necrosis factor a (TNFa) expression that was no
longer detectable by the second week (Figure 3F). There were no
CD4 responses from 8007, and neither CD4 nor CD8 T cells from
5006 expressed intracellular cytokines (data not shown). T cell ana-
lyses were not performed for 8007 following the second postnatal vec-
tor challenge (PVC). More ﬂuctuations in alanine transaminase
(ALT) and aspartate transaminase (AST) were observed in 5006
following vector challenge, whereas transaminases remained gener-
ally stable and unchanged in 8007 (Figure 3G). Despite this, no gross
tumors or histological evidence of inﬂammation or mitotic events
were detected at liver biopsy (performed between 6 and 49 months,
data not shown).1848 Molecular Therapy Vol. 25 No 8 August 2017To address genotoxic potential, we analyzed vector-genome junctions
(integration sites [ISs]) on serial liver biopsies by linear ampliﬁca-
tion-mediated (LAM)-PCR (Figure 4A). 3,749,785 AAV-derived
sequencing reads lead to the identiﬁcation of 128 ISs, of which 119
were uniquely mappable to the macaque genome, whereas nine ISs
were mappable to multiple loci (Table 2). Next, we analyzed the ten
most prominent ISs through a semiquantitative estimation of the
clonal size and found that no particular ISs were retrieved from
consecutive biopsies (Figure 4B). One IS was found within the geno-
toxicity-associated LMO2 gene in 5002, but was absent at later time
points. No particular IS was repeatedly isolated from different ani-
mals. We observed no preferential integration within gene coding
or nearby regions (Figure 4D) and no chromosomal integration hot-
spots when compared to a synthetic random dataset (Figure 4C).
Although 8.4% of ISs were found to occur within cancer-related genes
(included in the Cancer Gene Consortium, cBio, and retroviral-
tagged cancer gene databases), this did not signiﬁcantly differ from
the 8.9% found in our synthetic random dataset. We compared
the frequency of retrieved ISs (vector-genome) and concatemeric
(vector-vector) junctions. The majority of retrieved sequences in
Table 2. IS Analysis in Sequential Liver Biopsies
ID Postnatal Challenge (Months)
Hepatic Integration Sequences and Concatemers
Biopsy Time Points (Months) Total IS Mappable IS IS/mg IS (%) Concatemers (%)
8006 – 18 427,064 3 2 100.0 0.0
8007 46 47 27 6 4 61.4 38.6
5002 – 24 608 111 74 87.4 12.6
5006 32 35 2 2 1.3 0.01 99.99
5007 – 49 550,809 6 4 100.0 0.0
Detailed summary of the IS retrieved by LAM-PCR. Total IS, number of retrieved sequences corresponding to vector-genome junctions; mappable IS, number of exactly mappable IS;
% IS and concatemers, relative sequence count with respect to vector positive reads. ID, identity number.
www.moleculartherapy.orgpre- and non-challenged animals corresponded to IS (87.4%–100%),
with only 0%–12.6% reﬂecting concatemers, suggesting that long-
term transgene expression results primarily from integrated AAV ge-
nomes (Table 2). LAM-PCR analysis conﬁrmed the re-appearance of
vector concatemeric structures only in vector-challenged animals at
similar time points, reﬂecting recent AAV transduction (38.6% con-
catemers versus 61.4% ISs in 8007 and 99.99% concatemers versus
0.01% ISs in 5006).
DISCUSSION
This is the longest reported follow-up of a clinically relevant macaque
model for long-term outcomes of AAV-IUGT. Here, we demonstrate
that a single AAV dose at 0.9G achieved durable and clinically rele-
vant expression in 4/6 treated animals, and longitudinal surveillance
conﬁrms the overall absence of pathogenicity and genotoxicity in the
treated offspring. The substantially higher expression in males and
the contribution of AAV integration to long-term expression were
novel and unexpected ﬁndings.
Males presented higher hFIX expression and hepatocyte transduc-
tion, and this sexual dimorphism in expression contrasts to studies
on adult macaques.20 These data should be interpreted with caution
due to the small numbers of subjects and our limited ability to biopsy
multiple lobes of the liver, which would have correlated better
with hFIX expression. Although males were over-represented in the
AAV8 group, both AAV8- and AAV5-treated females exhibited
lower expression levels, indicating that prenatal diagnosis of fetal
gender26 and larger IUGT doses may be required to overcome this
transduction barrier for other non-X-linked inherited diseases. This
also suggests that the transduction barrier in females probably origi-
nates at the level of surface receptors controlling vector entry into the
cell. Gender differences have also been reported in canines.27 A large
variation in hFIX levels was observed especially among AAV8-treated
animals due to the exceptionally low expression in 8007 (female) and
the supraphysiological expression in 8002 and 8006 (males). VCN
among AAV8 animals was similar at each time point, and there
was no notable maternal anti-AAV antibody production following
IUGT (data not shown), as we have previously reported.1 Compared
to AAV8 recipients, AAV5 recipients showed lower hFIX expression
and VCN, which may have resulted from the stronger and lengthier
humoral response evoked. The temporal decline in hepatic VCN(up to three log-folds) was not in linear proportion to the increase
in body weight, and we cannot currently explain this ﬁnding.
At the dose administered, IUGT recipients displayed similar expres-
sion kinetics as adult non-human primate (NHP), in which 1E+12
vg/kg of AAV-hFIX produced 20% expression, peaking at 15 days
with abrupt reversible immune-mediated loss.28 Subsequent expres-
sion of anti-AAV activity was relatively subdued but may still have
been high enough to block transduction from the second AAV
dose. We previously reported baseline AAV integration of 10%
from retrieved vector sequences acting in concert with episomal
AAV to produce sustained transgene expression post-IUGT.1 None-
theless, current data reveal a progressive loss of vector episomes, due
to liver growth, suggesting that sustained vector persistence and
transgene expression is chieﬂy due to integrated vector forms. How-
ever, at late time points, both low VCN and episomal vector forms
may have been the result of repeated sampling within the same
hepatic area (allowing for ﬁbrosis and regeneration) and thus are
not reﬂective of non-biopsied areas. It would have been ideal to obtain
random samples across the liver at each time point, but at greater
physiological cost to the infants. Although still controversial, the gen-
otoxic potential of AAV constitutes an unlikely but potentially major
safety concern and requires lifelong surveillance. Despite the afore-
mentioned high retrieval frequencies, ISs were distributed genome-
wide, indicating the lack of preferential integration. One IS was found
within the genotoxicity-associated LMO2 gene in 5002 but was absent
at later time points, and no further integration hotspots or single
events were located within genes previously associated with AAV-
driven liver cancer development. Accordingly, over 6 years post-
treatment, no tumors were observed. These data suggest a low
likelihood of malignant transformation and reassure us of its suit-
ability for clinical use.
The 0.9G fetus is clearly immune competent and this inﬂuences long-
term transgene expression. However, the sustained binding antibody
expression following AAV-IUGT, with no loss of transgene expres-
sion in the majority of treated animals, suggests a larger contribution
from non-neutralizing antibodies. The fetal immune system may be
reactive but less efﬁcient at clearing foreign antigens at this develop-
mental stage, thus making late-gestation IUGT a useful intervention
for genetic diagnoses made in advanced pregnancy.29,30 Despite theMolecular Therapy Vol. 25 No 8 August 2017 1849
Molecular Therapyhigh dose of AAV8 used, only 8007’s transgene expression did not
peak early and did not reach our target of 1% hFIX during the ﬁrst
few months of life. The prolonged initial anti-AAV8 IgG response,
the one- to two-log folds lower hepatic VCN (compared to males),
and the transient spike in NAb and T cell cytokines suggest robust
sensitization to AAV from ﬁrst exposure. It is likely that the poor
initial hepatocyte transduction caused consistently low transgene
expression and failed to achieve liver-mediated tolerance, a key factor
for sustained therapeutic expression.31–33 The failure to increase he-
patic transduction despite two PVC suggests the presence of speciﬁc
unidentiﬁed inhibitors. Cross-reactivity of anti-AAV8 antibodies for
AAV5 capsid proteins and vice versa is unlikely, and the use of an
alternate serotype was, at this dose, insufﬁcient to overcome this
immune barrier.34–36 Inﬂammation-mediated mechanisms inhibiting
hFIX are also unlikely because ALT levels remained within normal
limits before and after PVC. We did not do T cell assays serially, so
we cannot correlate T cell responses to AAV with transaminases.
AST was transiently increased in 5006 in the month following post-
natal injection, with rapid resolution to baseline, whereas it remained
at normal levels in 8007. Even with transient T cell activation, histo-
logical examination conﬁrmed the absence of inﬂammation and he-
patocyte destruction, suggesting that the mechanism of failed expres-
sion may differ from the inﬂammation-driven transgene loss found in
adult humans that can be overcome with a short course of steroids.25
Although transgene expression was not measurably improved in 5006
with PVC, the absence of activated T cells despite transient NAb
expression and higher frequency of post-challenge concatemers sug-
gest that repeated vector administration can be safely performed but
requires optimization.
Naturally acquired NAbs to AAV5 and AAV8 usually accompany the
development of high titers of anti-AAV2 NAbs, and their presence in
children is usually transient.37 Although our macaques not were
screened for anti-AAV2 NAbs, this will be an important investigation
in planning PVC for IUGT recipients, especially because the preva-
lence of acquired anti-AAV2 increases with age. In vitro assessment
of neutralizing antibodies, cross-reacting IgG, and reactive T cells
will be crucial when evaluating an IUGT recipient’s suitability for
postnatal vector re-administration, and future clinical use may also
include immunomodulation to abrogate their effects.28,38 The PVC
dose here was kept to the lowest used in clinical trials in order tomini-
mize adverse immune reactions.25 In the absence of pre-existing in-
hibitors, we may expect a larger dose to overcome the transduction
barrier and achieve therapeutic expression in under-expressing
subjects.
Our study demonstrates the potential usefulness of the AAV-IUGT
approach to hereditary genetic conditions, with potential early
pathology due to its high efﬁcacy and somewhat safe clinical and
biochemical toxicity proﬁle. It must be acknowledged that the
observed long-term expression is mediated almost exclusively by
AAV insertional mechanisms, and the potential for oncogenesis
cannot be excluded yet. In life-threatening conditions or diseases
conferring substantial morbidity presenting early in life, AAV-1850 Molecular Therapy Vol. 25 No 8 August 2017IUGT is safe and effective. For these reasons and other widely
described advantages, even late-gestation gene transfer may be pref-
erable to treatment in early childhood.23 Precedents have been set
with the early treatment of severe combined immunodeﬁciencies
in young children, in whom the substantial beneﬁts of stem cell
gene therapy outweigh the risk of leukemogenesis.39,40 Integration
occurred more frequently than we anticipated from adult animal
data, likely due to the highly open structure of the fetal genome.41
In the practical context, a decision for AAV-IUGT will require life-
long surveillance for vector-related complications, including liver
cancer. It is certainly reassuring that at least no hotspots were discov-
ered. A clear distinction in expression efﬁcacy is observed between
males and females, which could mean that AAV-IUGT may be
limited in its initial application to X-linked disorders or male fetuses.
Although perhaps of limited prenatal use for bleeding disorders,
AAV-IUGT can be also tailored—by optimizing serotype, gestational
age, and dose—to a variety of life-threatening conditions, providing a
promising early clinical intervention that may inﬂuence the develop-
ment of personalized medicine.
MATERIALS AND METHODS
Animal Experiments, IUGT, and Surveillance
All procedures were performed in Macaca fascicularis, strictly
adhering to recommendations from the Institutional Animal Care
and Use Committee (IACUC) at the National University of Singapore
and Singapore Health Services Pte (IACUC 2009-SHS-512). In vivo
work was conducted at the SingHealth Experimental Medicine Centre
(Singapore), accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care International (AAALAC).
Fetal injections, together with prenatal and postnatal surveillance,
have been described previously.1,24 Brieﬂy, macaque fetuses were in-
jected with 4E+12 vg of scAAV-LP1-hFIX co-vector pseudotypes 8 or
5 at 0.9G based on pre-existing maternal seropositivity (Table 1).34
Offspring were delivered surgically and monitored for tissue-speciﬁc
hFIX expression and toxicity.1,24 Serial biopsies of the liver were per-
formed either by open midline laparotomy, during which additional
samples of omentum, skin, subcutaneous fat, and skeletal muscle were
obtained,24 or with a minimally invasive approach by passing a Quick
Core needle (Cook Medical) through a superﬁcial skin incision into
the liver under direct ultrasound guidance to obtain core biopsies.
All procedures were performed under general anesthesia.
Molecular Analyses
Quantiﬁcation of vector DNA content in serum and tissues was per-
formed by qPCR as previously described using 100 nM of each
primer1 (Table S2). VCN was calculated per 6.6 pg of DNA in diploid
cells. Expression of hFIX was determined by sandwich ELISA with
anti-hFIX Capture Antibody (1:100 dilution).34
Generation of AAV8 and AAV5 Peptide Libraries for T Cell
Intracellular Cell Staining
AAV8 (GenBank AF513852.1) and AAV5 (NCBI RefSeq NC_
006152.1 and GenBank AF085716.1) capsid protein sequences ob-
tained from NCBI were used to generate the AAV8 and AAV5
www.moleculartherapy.orgpeptide pools, respectively.42–44 Peptides generated from VP1, VP2,
and VP3 capsid proteins of both serotypes were prepared as 15-mer
overlapping by 10–12 amino acids (thinkpeptides, ProImmune).
Peptides were resuspended in water at a stock concentration of
5–10 mg/mL, and pools were prepared at a ﬁnal concentration of
2.5 mg/mL in PBS per peptide (Table S1).
Immunological Analyses
Humoral response: the presence of binding Abs reactive against the
vector capsid (AAV) and transgene (hFIX) and anti-AAV NAbs
were determined by semiquantitative sandwich ELISA and in-vitro
inhibition assays of GFP transduction of 293T cells respectively,
described previously.1 The negative and positive thresholds of the
semiquantitative anti-AAV ELISA were determined from the read-
outs of immunologically naive infant macaques not exposed to the
vector and from adult macaques immunized with each vector.
Cell-mediated response: T cell activity was analyzed following vector
challenge by intracellular cell staining (ICS) in a protocol adapted
from Li and colleagues.45 Peripheral blood mononuclear cells
(PBMNCs) collected from IUGT recipients and naive adult NHP
were isolated by density centrifugation using Ficoll-Paque and cryo-
preserved in DMSO (both Sigma-Aldrich) with fetal bovine serum
(FBS) (GIBCO, Life Technologies) and Dulbecco’s Modiﬁed Eagle’s
medium (GIBCO) in a ratio of 1:4:5 until analysis.46 Cells were
rapidly thawed, washed with sterile PBS, and incubated overnight
in RPMI 1640 (Life Technologies) with 10% FBS and 1% penicillin-
streptomycin (GIBCO) at 37C in 5% CO2. Treated NHP cells were
washed with Hank’s Balanced Salt Solution (Sigma-Aldrich) supple-
mented with 2 units/mL of DNase I (Thermo-Scientiﬁc), resuspended
in RPMI 1640, and stimulated with the relevant AAV capsid peptide
pool by 6-hr incubation in the presence of anti-CD28 (clone CD28.2),
anti-CD49d (clone 9F10), and Brefeldin A. Naive NHP cells were
ﬁxed in 4% paraformaldehyde (PFA) for 10 min following overnight
incubation and washing, centrifuged at 400 g for 15 min, and resus-
pended in 1 mL of ﬂuorescence-activated cell sorting (FACS) buffer
(1% BSA in PBS).
To analyze AAV8 capsid-speciﬁc CD8+ and CD4+ T cells, the sub-
ject’s stimulated PBMNC cells were stained with LIVE/DEAD Fixable
Violet Dead Cell stain kit Paciﬁc Blue (Invitrogen) and incubated with
the following antibodies for 30 min in the dark at 4C: anti-CD14-
Paciﬁc Blue (clone M5E2), anti-CD16-Paciﬁc Blue (clone 3G8),
anti-CD20-Paciﬁc Blue (clone 2H7, AbD serotec), anti-CD8-APC-
H7 (clone SK1), anti-CD4-Alexa700 (clone OKT4; eBioscience),
anti-CD95-PE-Cy5 (clone DX2), anti-CD28-PE-Texas Red (clone
CD28.2; Beckman Coulter), and anti-CCR7-PE (clone 150503;
R&D Systems). Cells incubated without peptides were used as nega-
tive controls, whereas positive controls consisted of PBMNCs stimu-
lated with phorbol 12-myristate 13-acetate (ﬁnal concentration of
0.05 mg/mL) and ionomycin (ﬁnal concentration of 5 mg/mL). Cells
were permeabilized with Cytoﬁx/Cytoperm for 20 min at room tem-
perature. Intracellular staining was performed with anti-IFN-g-APC,
anti-IL-2-FITC, anti-TNF-a-PE-Cy7, and anti-CD3-PerCP-Cy5.5 for30 min at 4C. Cells were washed with Cytoﬁx/Cytoperm once, ﬁxed
with 4% PFA, and then analyzed by FACS. Single-color controls were
provided using CompBeads Anti-Mouse, Anti-Rat Ig kappa, and
FITC single color CompBeads (BD Biosciences, unless stated).
Live cells were singly gated to exclude CD14+, CD16+, and CD20+
and dead cells. Live CD3+ cells were gated for CD8+ and CD4+ indi-
vidually, then gated for CD95 and CD28. Putative effector cells
(CD95hiCD28hi) were analyzed for IL-2 and IFN-g or IL-2 and
TNF-a. Putative memory cells (CD95intCD28low) were gated onto
CCR7. Central memory (TCM, CCR7hi) and effector memory
(TEM, CCR7low) T-lymphocyte subsets were gated for IL-2, inter-
feron g (IFN-g), and TNF-a. Positive samples were identiﬁed if at
least 0.05% of the subpopulation showed staining for a particular
cytokine.45 Flow cytometry was performed using LSR Fortessa and
FACSDiva software (BD Biosciences). Post-acquisition analyses
were performed with Summit 4.2 (Beckman-Coulter).
Histology
Fixed liver biopsy specimens were stained with H&E24 to assess for
changes in cell architecture and nuclear atypia and for inﬂammatory
cell inﬁltration.
ISs Analyses by LAM-PCR and Next-Generation Sequencing
LAM-PCR was performed47 with primers listed in Table S2. Brieﬂy,
products from two linear-PCR ampliﬁcation steps underwent restric-
tion digest with MseI and MluCI for subsequent adaptor ligation.
Two nested PCRs were then performed using vector- and adaptor-
speciﬁc primers, and an additional PCR step allowed library prepara-
tion for MiSeq sequencing (Illumina). The resulting raw sequences
were analyzed by automated bioinformatical tools for quality-ﬁlter,
vector trimming, and identiﬁcation of vector-genome (ISs) and vec-
tor-vector (concatemers) junctions. ISs were mapped to the macaque
genome using University of California Santa Cruz (UCSC) BLAT
tools and analyzed by automated data mining tools to characterize
the vector’s integration proﬁle.48
Postnatal Vector Challenge
Female offspring 5006 and 8007 were subjected to one or two PVC,
respectively (Figures 1C and 1E). Anti-capsid and anti-hFIX anti-
bodies, liver transaminases, hematological indices, hepatic VCN,
and liver histology were assessed just prior to PVC. Under general
anesthesia (GA), animals received a slow peripheral intravenous
(IV) injection and were monitored for 15 min during and after the
infusion. Post-PVC hematological indices, transaminases, and hFIX
levels were monitored bi-weekly and humoral and cell-mediated im-
mune assays were monitored weekly for the ﬁrst month. 3 months
later, animals underwent ultrasound (US)-guided liver biopsy with
Quick Core biopsy needles (Cook Medical) for analysis of VCN
and inﬂammatory inﬁltrates.
Statistical Analyses
Results were analyzed using statistical software GraphPad Prism
version 6.04 (GraphPad Software). Data are shown as mean (± SD)
and analyzed using unpaired t tests with Welch’s correction forMolecular Therapy Vol. 25 No 8 August 2017 1851
Molecular Therapyunequal SD; p < 0.05 was considered signiﬁcant. Frequency of
retrieval of integration sequences from tissue samples of subjects
was compared by Fisher’s exact test.
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